Amphotericin B serum concentrations during therapy.
- 1 June 1970
- journal article
- Vol. 19 (6) , 955-9
Abstract
Therapeutic outcome of patients being treated for systemic mycoses with amphotericin B is possibly related to the serum concentrations of this drug that are produced in these patients. Because current data are conflicting, the magnitude of these concentrations was restudied by using a bioassay which gave precise and accurate results. The highest of 155 serum concentrations was 2.01 mug/ml. Mean concentrations were 1.21, 0.62, and 0.32 mug/ml, at 1, 18, and 42 hr, respectively, after intravenous infusion of amphotericin B. This drug was detected in serum 7 weeks after completion of treatment, but it could not be detected 13 weeks after treatment. Drug levels did not appreciably decrease in serum stored for 8 to 9 months at - 10 C. Unequal serum content in assay tubes and measurement of assay turbidity by visual inspection may explain previously reported amphotericin B levels of 3.0 to 12.5 mug/ml.This publication has 21 references indexed in Scilit:
- A Pharmacologic Guide to the Clinical Use of Amphotericin BThe Journal of Infectious Diseases, 1969
- Methods and significance of in vitro testing of bacterial sensitivity to drugsThe American Journal of Medicine, 1965
- Bacterial endocarditisThe American Journal of Medicine, 1965
- FUNGISTATIC EFFECTS OF CELL FREE HUMAN SERUMThe Lancet Healthy Longevity, 1961
- Inhibition of Growth of Pathogenic Yeasts by Human Serum*Journal of Investigative Dermatology, 1961
- The Management of Bacterial EndocarditisArchives of internal medicine (1960), 1960
- The use of amphotericin B in the treatment of coccidioidal diseaseThe American Journal of Medicine, 1959
- Current status of amphotericin B in the treatment of the systemic fungus infectionsJournal of Chronic Diseases, 1959
- Protection of Fungi against Polyene Antibiotics by SterolsScience, 1958
- Coccidioidomycosis and its treatment with amphotericin BThe American Journal of Medicine, 1958